Search Results
You are looking at 1 - 3 of 3 items for
- Author: David E Neal x
- Refine by access: All content x
Adam W Nelson
Adam W Nelson
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by Adam W Nelson in
Google Scholar
PubMed
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by Adam W Nelson in
Google Scholar
PubMed
Wayne D Tilley
Wayne D Tilley
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
David E Neal
David E Neal
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by David E Neal in
Google Scholar
PubMed
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by David E Neal in
Google Scholar
PubMed
Jason S Carroll
Jason S Carroll
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by Jason S Carroll in
Google Scholar
PubMed
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Department of Urology Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
Dame Roma Mitchell Cancer Research Laboratories Faculty of Health Sciences, School of Medicine, The University of Adelaide, Level 4, Hanson Institute Building, DX Number 650 801, Adelaide, South Australia 5000, Australia
Department of Oncology University of Cambridge, Cambridge CB2 2QQ, UK
Search for other papers by Jason S Carroll in
Google Scholar
PubMed
Prostate cancer is the commonest, non-cutaneous cancer in men. At present, there is no cure for the advanced, castration-resistant form of the disease. Estrogen has been shown to be important in prostate carcinogenesis, with evidence resulting from epidemiological, cancer cell line, human tissue and animal studies. The prostate expresses both estrogen receptor alpha (ERA) and estrogen receptor beta (ERB). Most evidence suggests that ERA mediates the harmful effects of estrogen in the prostate, whereas ERB is tumour suppressive, but trials of ERB-selective agents have not translated into improved clinical outcomes. The role of ERB in the prostate remains unclear and there is increasing evidence that isoforms of ERB may be oncogenic. Detailed study of ERB and ERB isoforms in the prostate is required to establish their cell-specific roles, in order to determine if therapies can be directed towards ERB-dependent pathways. In this review, we summarise evidence on the role of ERB in prostate cancer and highlight areas for future research.
Benjamin C Thomas
Benjamin C Thomas
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Benjamin C Thomas in
Google Scholar
PubMed
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Benjamin C Thomas in
Google Scholar
PubMed
Jonathan D Kay
Jonathan D Kay
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Jonathan D Kay in
Google Scholar
PubMed
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Jonathan D Kay in
Google Scholar
PubMed
Suraj Menon
Suraj Menon
Bioinformatics and Statistics Core Facility, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Astra Zeneca, 2 Riverside, Granta Park, Cambridge, UK
Search for other papers by Suraj Menon in
Google Scholar
PubMed
Astra Zeneca, 2 Riverside, Granta Park, Cambridge, UK
Search for other papers by Suraj Menon in
Google Scholar
PubMed
Sarah L Vowler
Sarah L Vowler
Bioinformatics and Statistics Core Facility, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Astra Zeneca, 2 Riverside, Granta Park, Cambridge, UK
Search for other papers by Sarah L Vowler in
Google Scholar
PubMed
Astra Zeneca, 2 Riverside, Granta Park, Cambridge, UK
Search for other papers by Sarah L Vowler in
Google Scholar
PubMed
Sarah N Dawson
Sarah N Dawson
Bioinformatics and Statistics Core Facility, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Sarah N Dawson in
Google Scholar
PubMed
Search for other papers by Sarah N Dawson in
Google Scholar
PubMed
Laura J Bucklow
Laura J Bucklow
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Laura J Bucklow in
Google Scholar
PubMed
Search for other papers by Laura J Bucklow in
Google Scholar
PubMed
Hayley J Luxton
Hayley J Luxton
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Hayley J Luxton in
Google Scholar
PubMed
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Hayley J Luxton in
Google Scholar
PubMed
Thomas Johnston
Thomas Johnston
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Thomas Johnston in
Google Scholar
PubMed
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Thomas Johnston in
Google Scholar
PubMed
Charlie E Massie
Charlie E Massie
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Molecular and Computational Diagnostics Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Charlie E Massie in
Google Scholar
PubMed
Molecular and Computational Diagnostics Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Charlie E Massie in
Google Scholar
PubMed
Michelle Pugh
Michelle Pugh
Genomics Core Facility, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Michelle Pugh in
Google Scholar
PubMed
Search for other papers by Michelle Pugh in
Google Scholar
PubMed
Anne Y Warren
Anne Y Warren
Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Search for other papers by Anne Y Warren in
Google Scholar
PubMed
Search for other papers by Anne Y Warren in
Google Scholar
PubMed
Peter Barker
Peter Barker
National Institute for Health Research Cambridge Biomedical Research Centre Core Biochemistry Assay Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Search for other papers by Peter Barker in
Google Scholar
PubMed
Search for other papers by Peter Barker in
Google Scholar
PubMed
Keith Burling
Keith Burling
National Institute for Health Research Cambridge Biomedical Research Centre Core Biochemistry Assay Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Search for other papers by Keith Burling in
Google Scholar
PubMed
Search for other papers by Keith Burling in
Google Scholar
PubMed
Andy G Lynch
Andy G Lynch
Computational Biology Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Andy G Lynch in
Google Scholar
PubMed
Search for other papers by Andy G Lynch in
Google Scholar
PubMed
Anne George
Anne George
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Anne George in
Google Scholar
PubMed
Search for other papers by Anne George in
Google Scholar
PubMed
Johanna Burge
Johanna Burge
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Johanna Burge in
Google Scholar
PubMed
Search for other papers by Johanna Burge in
Google Scholar
PubMed
Marie Corcoran
Marie Corcoran
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Marie Corcoran in
Google Scholar
PubMed
Search for other papers by Marie Corcoran in
Google Scholar
PubMed
Sara Stearn
Sara Stearn
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Sara Stearn in
Google Scholar
PubMed
Search for other papers by Sara Stearn in
Google Scholar
PubMed
Alastair D Lamb
Alastair D Lamb
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Alastair D Lamb in
Google Scholar
PubMed
Search for other papers by Alastair D Lamb in
Google Scholar
PubMed
Naomi L Sharma
Naomi L Sharma
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Naomi L Sharma in
Google Scholar
PubMed
Search for other papers by Naomi L Sharma in
Google Scholar
PubMed
Greg L Shaw
Greg L Shaw
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
University College Hospital at Westmoreland Street, London, UK
Search for other papers by Greg L Shaw in
Google Scholar
PubMed
University College Hospital at Westmoreland Street, London, UK
Search for other papers by Greg L Shaw in
Google Scholar
PubMed
David E Neal
David E Neal
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Headington, Oxford, UK
Search for other papers by David E Neal in
Google Scholar
PubMed
Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Headington, Oxford, UK
Search for other papers by David E Neal in
Google Scholar
PubMed
Hayley C Whitaker
Hayley C Whitaker
Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Hayley C Whitaker in
Google Scholar
PubMed
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Hayley C Whitaker in
Google Scholar
PubMed
Due to increased sensitivity, the expression of circulating nucleotides is rapidly gaining popularity in cancer diagnosis. Whole blood mRNA has been used in studies on a number of cancers, most notably two separate studies that used whole blood mRNA to define non-overlapping signatures of prostate cancer that has become castration independent. Prostate cancer is known to rely on androgens for initial growth, and there is increasing evidence on the importance of the androgen axis in advanced disease. Using whole blood mRNA samples from patients with prostate cancer, we have identified the four-gene panel of FAM129A, MME, KRT7 and SOD2 in circulating mRNA that are differentially expressed in a discovery cohort of metastatic samples. Validation of these genes at the mRNA and protein level was undertaken in additional cohorts defined by risk of relapse following surgery and hormone status. All the four genes were downregulated at the mRNA level in the circulation and in primary tissue, but this was not always reflected in tissue protein expression. MME demonstrated significant differences in the hormone cohorts, whereas FAM129A is downregulated at the mRNA level but is raised at the protein level in tumours. Using published ChIP-seq data, we have demonstrated that this may be due to AR binding at the FAM129A and MME loci in multiple cell lines. These data suggest that whole blood mRNA of androgen-regulated genes has the potential to be used for diagnosis and monitoring of prostate cancer.
Charles E Massie
Charles E Massie
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Charles E Massie in
Google Scholar
PubMed
Search for other papers by Charles E Massie in
Google Scholar
PubMed
Inmaculada Spiteri
Inmaculada Spiteri
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Inmaculada Spiteri in
Google Scholar
PubMed
Search for other papers by Inmaculada Spiteri in
Google Scholar
PubMed
Helen Ross-Adams
Helen Ross-Adams
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Helen Ross-Adams in
Google Scholar
PubMed
Search for other papers by Helen Ross-Adams in
Google Scholar
PubMed
Hayley Luxton
Hayley Luxton
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Hayley Luxton in
Google Scholar
PubMed
Search for other papers by Hayley Luxton in
Google Scholar
PubMed
Jonathan Kay
Jonathan Kay
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Jonathan Kay in
Google Scholar
PubMed
Search for other papers by Jonathan Kay in
Google Scholar
PubMed
Hayley C Whitaker
Hayley C Whitaker
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Hayley C Whitaker in
Google Scholar
PubMed
Search for other papers by Hayley C Whitaker in
Google Scholar
PubMed
Mark J Dunning
Mark J Dunning
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Mark J Dunning in
Google Scholar
PubMed
Search for other papers by Mark J Dunning in
Google Scholar
PubMed
Alastair D Lamb
Alastair D Lamb
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Alastair D Lamb in
Google Scholar
PubMed
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Alastair D Lamb in
Google Scholar
PubMed
Antonio Ramos-Montoya
Antonio Ramos-Montoya
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Antonio Ramos-Montoya in
Google Scholar
PubMed
Search for other papers by Antonio Ramos-Montoya in
Google Scholar
PubMed
Daniel S Brewer
Daniel S Brewer
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Daniel S Brewer in
Google Scholar
PubMed
Search for other papers by Daniel S Brewer in
Google Scholar
PubMed
Colin S Cooper
Colin S Cooper
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Colin S Cooper in
Google Scholar
PubMed
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Colin S Cooper in
Google Scholar
PubMed
Rosalind Eeles
Rosalind Eeles
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Rosalind Eeles in
Google Scholar
PubMed
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Rosalind Eeles in
Google Scholar
PubMed
UK Prostate ICGC Group
UK Prostate ICGC Group
Search for other papers by UK Prostate ICGC Group in
Google Scholar
PubMed
Search for other papers by UK Prostate ICGC Group in
Google Scholar
PubMed
Anne Y Warren
Anne Y Warren
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Anne Y Warren in
Google Scholar
PubMed
Search for other papers by Anne Y Warren in
Google Scholar
PubMed
Simon Tavaré
Simon Tavaré
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Simon Tavaré in
Google Scholar
PubMed
Search for other papers by Simon Tavaré in
Google Scholar
PubMed
David E Neal
David E Neal
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by David E Neal in
Google Scholar
PubMed
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by David E Neal in
Google Scholar
PubMed
Andy G Lynch
Andy G Lynch
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Andy G Lynch in
Google Scholar
PubMed
Search for other papers by Andy G Lynch in
Google Scholar
PubMed
Prostate cancer is the most common cancer in men, resulting in over 10 000 deaths/year in the UK. Sequencing and copy number analysis of primary tumours has revealed heterogeneity within tumours and an absence of recurrent founder mutations, consistent with non-genetic disease initiating events. Using methylation profiling in a series of multi-focal prostate tumours, we identify promoter methylation of the transcription factor HES5 as an early event in prostate tumourigenesis. We confirm that this epigenetic alteration occurs in 86–97% of cases in two independent prostate cancer cohorts (n=49 and n=39 tumour–normal pairs). Treatment of prostate cancer cells with the demethylating agent 5-aza-2′-deoxycytidine increased HES5 expression and downregulated its transcriptional target HES6, consistent with functional silencing of the HES5 gene in prostate cancer. Finally, we identify and test a transcriptional module involving the AR, ERG, HES1 and HES6 and propose a model for the impact of HES5 silencing on tumourigenesis as a starting point for future functional studies.
